Skip to content

Author

Woochan Hwang

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Aug 2026

Danburstotug, an anti-PD-L1 antibody, in relapsed/refractory extra-nodal natural killer/T-cell lymphoma: The phase 2 DISTINKT study.

Relapsed/refractory extra-nodal natural killer/T-cell lymphoma (R/R ENKTL) has limited treatment options. Danburstotug, an antibody targeting programmed death-ligand 1 (PD-L1), was evaluated in adults with R/R ENKTL in a phase 2, open-label study (NCT04414163). Danburstotug 20 mg/kg was administered intravenously every...

W. Kim, S. Kim, Jae-Cheol Jo et al. · 0 citations
Review Sep 2026

Heterogeneity of breast and nodal response to neoadjuvant pembrolizumab-based chemoimmunotherapy in early triple-negative breast cancer and its clinical significance.

AIMS To characterize the heterogeneity of pathological responses in the breast and regional lymph nodes after neoadjuvant pembrolizumab-based chemoimmunotherapy in early-stage triple-negative breast cancer (TNBC) and to explore their clinical implications. METHODS AND RESULTS A total of 203 patients with TNBC treated...

Jiwon Koh, K. J. Suh, H. Park et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.